Biodesix, Inc. (BDSX)
Biodesix, Inc. is a data-driven diagnostic solutions company specializing in blood-based lung cancer tests. Their offerings aid in risk assessment, treatment guidance, and companion diagnostics for biopharmaceutical companies.
Company Overview
Biodesix is a data-driven diagnostic innovator, providing blood-based lung cancer solutions that improve patient outcomes and treatment decisions. With proprietary tests and strategic partnerships, Biodesix is positioned to capitalize on the growing demand for precision diagnostics and personalized medicine in the lung cancer space.
Investment Thesis
Biodesix presents a compelling investment opportunity due to its focus on the high-growth lung cancer diagnostics market. The company's proprietary blood-based tests offer a less invasive and more cost-effective alternative to traditional diagnostic methods. Key value drivers include increasing adoption of the Nodify Lung testing strategy, expansion of the GeneStrat and VeriStrat assays, and strategic partnerships with biopharmaceutical companies for companion diagnostics development. With a market capitalization of $0.08 billion, Biodesix has significant upside potential as it executes its commercial strategy and expands its product portfolio. A gross margin of 79.8% indicates strong pricing power and scalability. Upcoming data releases from clinical studies and potential FDA approvals could serve as catalysts for stock appreciation. Successful execution of its biopharmaceutical partnerships and expansion of its testing services could drive revenue growth and improve profitability.
Key Highlights
- Market Cap of $0.08 billion indicates a small-cap company with potential for significant growth.
- Gross Margin of 79.8% demonstrates strong pricing power and efficient cost management.
- P/E Ratio of -1.97 reflects current losses but also potential for future earnings growth.
- Beta of 0.68 suggests lower volatility compared to the overall market.
- Partnership with Bio-Rad Laboratories expands testing capabilities and market reach.
Competitors
Strengths
- Proprietary blood-based diagnostic tests.
- Data-driven approach to diagnostics.
- Established relationships with biopharmaceutical companies.
- Strong gross margin.
Weaknesses
- Small market capitalization.
- History of losses.
- Limited commercial infrastructure.
- Dependence on a limited number of products.
Catalysts
- Upcoming: Data releases from clinical studies of Nodify Lung testing strategy.
- Upcoming: Potential FDA approvals for new diagnostic tests.
- Ongoing: Expansion of commercial partnerships with biopharmaceutical companies.
- Ongoing: Increasing adoption of blood-based diagnostic tests by physicians.
- Ongoing: Positive reimbursement decisions from payers.
Risks
- Potential: Competition from larger diagnostic companies with greater resources.
- Potential: Technological obsolescence of existing diagnostic tests.
- Potential: Regulatory hurdles and delays in obtaining approvals for new tests.
- Ongoing: Reimbursement challenges from payers.
- Ongoing: Dependence on a limited number of products for revenue generation.
Growth Opportunities
- Expansion of Nodify Lung Testing Strategy: The Nodify XL2 and Nodify CDT tests offer a non-invasive approach to assessing lung nodule malignancy risk. Increasing adoption by pulmonologists and radiologists represents a significant growth opportunity. The market for lung nodule assessment is estimated to be substantial, with millions of Americans undergoing chest imaging annually. Biodesix can capitalize on this by expanding its sales force, increasing marketing efforts, and securing favorable reimbursement coverage.
- Development and Commercialization of Companion Diagnostics: Partnering with biopharmaceutical companies to develop companion diagnostics for targeted therapies represents a high-growth opportunity. Companion diagnostics help identify patients most likely to respond to specific therapies, improving treatment outcomes and reducing healthcare costs. Biodesix's expertise in blood-based diagnostics and its established relationships with biopharmaceutical companies position it well to capture a significant share of this market.
- Geographic Expansion: Expanding into international markets represents another significant growth opportunity. Lung cancer is a global health problem, and Biodesix's tests could benefit patients worldwide. The company can pursue strategic partnerships with international distributors and establish a presence in key markets such as Europe and Asia. This expansion would diversify revenue streams and reduce reliance on the US market.
- Expansion of GeneStrat NGS Testing: The GeneStrat NGS test offers comprehensive genomic profiling of lung tumors from a blood sample. Expanding the test menu and increasing adoption by oncologists represents a growth opportunity. The market for NGS-based cancer diagnostics is growing rapidly, driven by the increasing use of targeted therapies and immunotherapies. Biodesix can capitalize on this by offering a comprehensive and cost-effective NGS testing solution.
- Strategic Acquisitions: Biodesix could pursue strategic acquisitions to expand its product portfolio, acquire new technologies, and increase its market share. Potential acquisition targets could include companies with complementary diagnostic tests, bioinformatics capabilities, or sales and marketing infrastructure. Strategic acquisitions could accelerate Biodesix's growth and enhance its competitive position.
Opportunities
- Increasing adoption of Nodify Lung testing strategy.
- Development and commercialization of companion diagnostics.
- Geographic expansion.
- Strategic acquisitions.
Threats
- Competition from larger diagnostic companies.
- Technological obsolescence.
- Regulatory changes.
- Reimbursement challenges.
Competitive Advantages
- Proprietary blood-based diagnostic tests.
- Data-driven approach to diagnostics.
- Established relationships with biopharmaceutical companies.
- Strong intellectual property portfolio.
About
Biodesix, Inc., founded in 2005 and headquartered in Boulder, Colorado, is a data-driven diagnostic solutions company focused on improving patient outcomes in lung disease. Originally named Elston Technologies, Inc., the company has evolved to offer a suite of blood-based diagnostic tests designed to address critical decision points in the lung cancer continuum. Biodesix's core offerings include the Nodify Lung Nodule Risk Assessment testing strategy, comprising the Nodify XL2 and Nodify CDT tests, which help physicians assess the risk of malignancy in suspicious lung nodules and guide appropriate treatment pathways. These tests aid in reclassifying risk, potentially reducing the need for invasive procedures. Furthermore, Biodesix provides GeneStrat ddPCR and VeriStrat tests, used in lung cancer diagnosis to measure tumor mutations and patient immune system status, informing prognosis and treatment decisions. The GeneStrat NGS test offers a 72-hour blood-based next-generation sequencing analysis. Beyond lung cancer, Biodesix partners with Bio-Rad Laboratories, Inc. to offer COVID-19 testing solutions under the Biodesix WorkSafe program, including the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test. Biodesix also provides diagnostic and clinical research services to biopharmaceutical companies, discovering, developing, and commercializing companion diagnostics to personalize treatment strategies.
What They Do
- Develop and commercialize blood-based diagnostic tests for lung cancer.
- Offer Nodify Lung Nodule Risk Assessment testing strategy to assess lung nodule malignancy risk.
- Provide GeneStrat ddPCR and VeriStrat tests for lung cancer diagnosis and treatment guidance.
- Offer GeneStrat NGS test for comprehensive genomic profiling of lung tumors.
- Partner with Bio-Rad Laboratories to offer COVID-19 testing solutions.
- Provide diagnostic and clinical research services to biopharmaceutical companies.
- Discover, develop, and commercialize companion diagnostics.
Business Model
- Sales of diagnostic tests to hospitals, clinics, and physicians.
- Diagnostic and clinical research services to biopharmaceutical companies.
- Development and commercialization of companion diagnostics in partnership with pharmaceutical companies.
- COVID-19 testing services.
Industry Context
The medical diagnostics industry is experiencing rapid growth, driven by advancements in genomics, proteomics, and personalized medicine. The lung cancer diagnostics market is particularly attractive, with a growing incidence of lung cancer and increasing demand for less invasive diagnostic methods. Biodesix competes with companies like ALGS, INMB, MRSN, NOTV and OKUR, which offer various diagnostic tests and services. The industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. Biodesix's data-driven approach and focus on blood-based diagnostics position it favorably within this dynamic landscape.
Key Customers
- Pulmonologists and radiologists
- Oncologists
- Biopharmaceutical companies
- Hospitals and clinics
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $22M | -$9M | $-1.16 |
| Q2 2025 | $20M | -$11M | $-1.56 |
| Q1 2025 | $18M | -$11M | $-1.52 |
| Q4 2024 | $20M | -$8M | $-1.13 |
Source: Company filings
Chart & Info
Price Chart
Biodesix, Inc. (BDSX) stock price: $6.23 (-0.23, -3.56%)
Why Bull
- •Recent insider buying suggests confidence in Biodesix's future growth, indicating insiders believe in the company's potential.
- •Community sentiment has shifted positively, with discussions highlighting the promising developments in their diagnostic technologies.
- •The company has made strides in partnerships, enhancing its market position and expanding its reach in the healthcare sector.
- •Recent product advancements have garnered attention, aligning with increasing demand for personalized medicine solutions.
Why Bear
- •Concerns over operational costs have surfaced, with some investors questioning the sustainability of current funding levels.
- •Market perception remains cautious, with bearish sentiment stemming from competitive pressures in the diagnostic space.
- •Recent earnings reports have raised eyebrows, prompting discussions around the company's ability to scale effectively.
- •Some community members express skepticism about the company's long-term growth strategy, citing potential regulatory hurdles ahead.
Latest News
-
Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
GlobeNewswire · Feb 12, 2026
-
Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Yahoo! Finance: BDSX News · Feb 12, 2026
-
Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
globenewswire.com · Feb 12, 2026
-
Insiders Are Still Scooping Up Under Armour and WR Berkley Shares
24/7 Wall St. · Jan 31, 2026
Technical Analysis
Rationale
AI-generated technical analysis for BDSX including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Biodesix, Inc. (BDSX) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for BDSX.
Make a Prediction
Set your price target for Biodesix, Inc. (BDSX), choose a timeframe, and track your prediction accuracy.
Current price: $6.23
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BDSX.
Price Targets
Wall Street price target analysis for BDSX.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 6/100
Revenue increased 45.3% YoY, reflecting moderate but steady business growth.
-
Gross Margin 10/100
Gross margin of 79.8% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 6/100
Revenue growth is driving operating leverage, meaning profits can grow faster than costs.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 10/100
Insiders bought +$51.90M net in recent filings, a strong confidence signal from those who know the company best.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates BDSX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Insiders Are Still Scooping Up Under Armour and WR Berkley Shares
Frequently Asked Questions
What does Biodesix, Inc. do?
Biodesix, Inc. is a data-driven diagnostic solutions company focused on improving patient outcomes in lung disease. The company develops and commercializes blood-based diagnostic tests that help physicians assess the risk of lung cancer, guide treatment decisions, and personalize therapy. Its core offerings include the Nodify Lung Nodule Risk Assessment testing strategy, GeneStrat ddPCR and VeriStrat tests, and GeneStrat NGS test. Biodesix also partners with biopharmaceutical companies to develop companion diagnostics and provides diagnostic and clinical research services.
Is BDSX stock a good buy?
BDSX stock presents a speculative investment opportunity with high potential upside and significant risks. The company's focus on the growing lung cancer diagnostics market and its proprietary blood-based tests are positive factors. However, its small market capitalization, history of losses, and dependence on a limited number of products are concerns. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in BDSX. Monitoring revenue growth, gross margin, and progress in securing partnerships and regulatory approvals is crucial.
What are the main risks for BDSX?
The main risks for BDSX include competition from larger diagnostic companies, technological obsolescence of existing diagnostic tests, regulatory hurdles and delays in obtaining approvals for new tests, reimbursement challenges from payers, and dependence on a limited number of products for revenue generation. The company's small size and limited resources make it vulnerable to these risks. Failure to successfully commercialize its products or secure favorable reimbursement coverage could negatively impact its financial performance and stock price.
Is BDSX a good stock to buy?
Whether BDSX is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the BDSX MoonshotScore?
The MoonshotScore for BDSX is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is BDSX data updated?
BDSX stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to BDSX is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for BDSX?
Growth catalysts for Biodesix, Inc. (BDSX) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Biodesix, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are BDSX's main competitors?
Biodesix, Inc. (BDSX) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether BDSX has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about BDSX?
Wall Street analyst coverage for BDSX includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is BDSX's market cap?
Market capitalization (market cap) for BDSX is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows BDSX's current market cap alongside enterprise value and other valuation metrics.
How has BDSX stock performed recently?
BDSX's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing BDSX's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in BDSX?
Key risk categories for BDSX include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures BDSX's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling BDSX?
Insider trading activity for BDSX tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is BDSX a good stock for beginners?
Biodesix, Inc. (BDSX) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is BDSX for first-time investors?
Every stock carries risk, including Biodesix, Inc. (BDSX). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like BDSX.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.